1. Home
  2. NVAX vs EVO Comparison

NVAX vs EVO Comparison

Compare NVAX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • EVO
  • Stock Information
  • Founded
  • NVAX 1987
  • EVO 1993
  • Country
  • NVAX United States
  • EVO Germany
  • Employees
  • NVAX N/A
  • EVO N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • EVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVAX Health Care
  • EVO Health Care
  • Exchange
  • NVAX Nasdaq
  • EVO Nasdaq
  • Market Cap
  • NVAX 1.3B
  • EVO 1.2B
  • IPO Year
  • NVAX 1995
  • EVO 2021
  • Fundamental
  • Price
  • NVAX $8.08
  • EVO $3.50
  • Analyst Decision
  • NVAX Buy
  • EVO Buy
  • Analyst Count
  • NVAX 7
  • EVO 2
  • Target Price
  • NVAX $14.29
  • EVO $5.40
  • AVG Volume (30 Days)
  • NVAX 6.9M
  • EVO 44.3K
  • Earning Date
  • NVAX 11-11-2025
  • EVO 11-05-2025
  • Dividend Yield
  • NVAX N/A
  • EVO N/A
  • EPS Growth
  • NVAX N/A
  • EVO N/A
  • EPS
  • NVAX 2.54
  • EVO N/A
  • Revenue
  • NVAX $1,078,718,000.00
  • EVO $912,894,891.00
  • Revenue This Year
  • NVAX $61.69
  • EVO $0.43
  • Revenue Next Year
  • NVAX N/A
  • EVO $9.72
  • P/E Ratio
  • NVAX $3.18
  • EVO N/A
  • Revenue Growth
  • NVAX 9.22
  • EVO N/A
  • 52 Week Low
  • NVAX $5.01
  • EVO $2.84
  • 52 Week High
  • NVAX $15.22
  • EVO $5.64
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 53.19
  • EVO 43.62
  • Support Level
  • NVAX $7.83
  • EVO $3.43
  • Resistance Level
  • NVAX $8.31
  • EVO $3.55
  • Average True Range (ATR)
  • NVAX 0.34
  • EVO 0.08
  • MACD
  • NVAX 0.01
  • EVO 0.02
  • Stochastic Oscillator
  • NVAX 78.70
  • EVO 63.64

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: